Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human SERPINB2 Anticorps:
anti-Mouse (Murine) SERPINB2 Anticorps:
anti-Rat (Rattus) SERPINB2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal SERPINB2 Primary Antibody pour ICC, IF - ABIN4352989
Poaty, Coullin, Peko, Dessen, Diatta, Valent, Leguern, Prévot, Gombé-Mbalawa, Candelier, Picard, Bernheim: Genome-wide high-resolution aCGH analysis of gestational choriocarcinomas. dans PLoS ONE 2012
Show all 4 Pubmed References
Human Polyclonal SERPINB2 Primary Antibody pour IHC (p), WB - ABIN390477
Di Bernardo, Matakidou, Eisen, Houlston,: Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. dans Lung cancer (Amsterdam, Netherlands) 2009
Show all 2 Pubmed References
Cow (Bovine) Polyclonal SERPINB2 Primary Antibody pour WB - ABIN2786668
Stutchbury, Al-Ejeh, Stillfried, Croucher, Andrews, Irving, Links, Ranson: Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. dans Molecular cancer therapeutics 2007
Show all 2 Pubmed References
PAI-2 likely plays a key role in cardiovascular disease through multiple pathophysiologic processes including racial dependency, platelet clot (Montrer TXNDC17 Anticorps) initiation and propagation, oxidative stress, inflammation effects on HDL (Montrer HSD11B1 Anticorps) metabolism and coagulation
This study is the first to associate enhancer RNAs with SERPINB2 and is the first demonstration of acquisition of NELF binding by enhancer RNAs on chromatin.
This study establishes a novel role for SerpinB2 in the stromal compartment in pancreatic ductal adenocarcinoma invasion through regulation of stromal remodelling
The variant of PAI-2 gene was associated with coronary artery disease and recurrent coronary event risk in Chinese Han population, in Xinjiang.
SerpinB2 plays an important role in proteostas
a total of 500 ESCC cases and 500 matched controls in a Southwest China population were evaluated for six SNPs in the exons of three Serpin genes (SerpinB5 (Montrer SERPINB5 Anticorps), SerpinB2, and SerpinE1 (Montrer SERPINE1 Anticorps)).
PAI-2 was up-regulated in tensioned keloid fibroblasts and normal fibroblasts, but more so in keloid cells. Knockdown of PAI2 reduced cell proliferation in fibroblasts under tension.
Soluble guanylate cyclase activators might alleviate or reverse vascular remodeling in pulmonary hypertension through the up-regulation of PAI-2.
We found no association between allele frequency and risk of multiples sclerosis for any single nucleotide polymorphism investigated for serpinb2
A role for SERPINB2 in patients with head and neck squamous cell carcinoma.
The efficient and rapid formation of uPA:PAI-2 complexes was thus shown to be associated with specific and rapid internalisation of PAI-2, which could be localised within endosomes and lysosomes
Data suggest that the function of keratinocyte SerpinB2 is protection of the stratum corneum from proteolysis via inhibition of urokinase, thereby maintaining the integrity and barrier function of the stratum corneum, particularly during times of skin inflammation
PAI-2 is a novel regulator of venous thrombus resolution, which modulates several pathways involving both inflammatory and uPA (Montrer PLAU Anticorps) activity mechanisms, distinct from PAI-1 (Montrer SERPINE1 Anticorps)
SerpinB2 has previously been implicated as a mediator of DMBA/TPA (Montrer PLAT Anticorps)-induced skin carcinogenesis
The presence of SerpinB2 on the surface of MPs provides a physiological mechanism whereby cancer cell SerpinB2 can reach the extracellular milieu and access urokinase plasminogen (Montrer PLG Anticorps) activator (uPA (Montrer PLAU Anticorps)).
Brain metastatic cells from lung cancer and breast cancer express high levels of anti-plasminogen (Montrer PLG Anticorps) activator (PA) serpins, including neuroserpin (Montrer SERPINI1 Anticorps) and serpin B2, to prevent plasmin (Montrer PLG Anticorps) generation and its metastasis-suppressive effects.
C/EBP-beta mediates both constitutive and LPS-induced serpinB2 mRNA expression in mouse embryonic fibroblasts and inflammatory primary macrophages.
Depletion PAI-2 resulted in NLRP3 (Montrer NLRP3 Anticorps)- and ASC (Montrer STS Anticorps)-dependent caspase-1 (Montrer CASP1 Anticorps) activation and IL-1beta (Montrer IL1B Anticorps) secretion in macrophages upon Toll-like receptor 2 (TLR2 (Montrer TLR2 Anticorps)) and TLR4 (Montrer TLR4 Anticorps) engagement.
SerpinB2 can be induced by lentiviral infection in vivo.
Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell- derived PAI-1.
, placental plasminogen activator inhibitor
, plasminogen activator inhibitor 2
, plasminogen activator inhibitor, type II (arginine-serpin)
, serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2
, serpin B2
, urokinase inhibitor
, serine proteinase inhibitor, clade B, member 2
, plasminogen activator inhibitor type 2
, plasminogen activator inhibitor, type 2 (arginine-serpin)
, serpin peptidase inhibitor, clade B (ovalbumin), member 2
, plasminogen activator inhibitor 2, macrophage
, plasminogen activator inhibitor, type II
, serine (or cysteine) proteinase inhibitor, clade B, member 2
, plasminogen activator inhibitor 2 type A
, serine (or cysteine) peptidase inhibitor, clade B, member 2
, plasminogen activator inhibitor-2
, serine/cysteine proteinase inhibitor, clade B (ovalbumin), member 2